

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claim 1. (currently amended) A pharmaceutical composition comprising (A) formoterol or a pharmaceutically acceptable salt thereof or a solvate of formoterol or said salt and (B) fluticasone propionate, wherein said (A) and (B) are in inhalable form.

Claim 2. (original) A composition according to claim 1 comprising a mixture of effective amounts of (A) and (B) together with a pharmaceutically acceptable carrier.

Claim 3. (original) A composition according to claim 1, in which (A) is formoterol fumarate.

Claim 4. (original) A composition according to claim 3, in which formoterol fumarate is in the form of the dihydrate thereof.

Claim 5. (original) A composition according to claim 1, which is in inhalable form.

Claim 6. (original) A composition according to claim 4, which is in inhalable form.

Claim 7. (original) A composition according to claim 5, which is an aerosol comprising a mixture of (A) and (B) in solution or dispersion in a propellant.

Claim 8. (original) A composition according to claim 7, in which (A) and (B) are in suspension in said propellant, which is a halogen-substituted hydrocarbon.

Claim 9. (original) A composition according to claim 8, in which (A) and (B), or each of (A) and (B), has an average particle diameter of up to 10  $\mu\text{m}$ .

Claim 10. (original) A composition according to claim 5, which is a nebulizable composition comprising a dispersion of (A) and (B) in an aqueous, organic or aqueous/organic medium.

Claim 11. (original) A composition according to claim 5, which is a dry powder comprising finely divided (A) and (B) optionally together with a pharmaceutically acceptable carrier in finely divided form.

Claim 12. (original) A composition according to claim 11, in which the carrier is present and is a saccharide.

Claim 13. (original) A composition according to claim 12, in which the carrier is lactose.

Claim 14. (original) A composition according to claim 11 in (A) or (B), or each of (A) and (B), has an average particle diameter of up to 10  $\mu\text{m}$ .

Claim 15. (original) A composition according to claim 1, in which the weight ratio of (A) to (B) is from 3:1 to 1:3000.

Claim 16. (original) A composition according to claim 15, in which said ratio is from 1:5 to 1:50.

Claim 17. (original) A composition according to claim 15, in which said ratio is from 1:10 to 1:25.

Claim 18. (original) A composition according to claim 1, which is a dry powder in a capsule, the capsule containing from 3 to 36 µg of (A) as formoterol fumarate dehydrate, from 25 to 500 µg of (B) and a pharmaceutically acceptable carrier in an amount to bring the total weight of dry powder to between 5 mg and 50 mg.

Claim 19. (original) A composition according to claim 1, which is a dry powder comprising, by weight, 3 to 36 parts of (A) as formoterol fumarate dehydrate, 25 to 500 parts of (B) and 4464 to 24972 parts of a pharmaceutically acceptable carrier.

Claim 20. (original) A method of treating an inflammatory or obstructive airways disease which comprises administering to a subject in need of such treatment an effective amount of a composition according to claim 1.